Selling Peptides Online: What the FDA Rules Actually Say in 2026

Is it legal to sell peptides online in the US?

It depends entirely on which peptide, how you market it, and whether it's intended for human consumption — there's no blanket yes or no. Under FD&C Act sections 201(g)(1) and 201(p), a peptide sold for human use is a drug, and an unapproved 'new drug' if it hasn't been found safe and effective, which makes its sale a violation of sections 301(d) and 505(a) absent FDA approval. That's the exact framework FDA cited against Gram Peptides in March 2026.

Food-derived peptides sit outside that framework. Hydrolyzed collagen and whey protein hydrolysates qualify as dietary substances under 21 U.S.C. 321(ff)(1) because they were marketed as food long before any drug investigation touched them, so they read, under a straightforward application of the statute, as lawful dietary ingredients you can sell under DSHEA. Synthetic research peptides don't fit that closed list, and that food-derived-versus-synthetic split is the single most useful filter for evaluating any peptide advertising rules before you build a store around a given SKU.

If your catalog leans toward GLP-1 analogs — semaglutide, tirzepatide, retatrutide — assume federal scrutiny is active, not theoretical. US enforcement is also only one jurisdiction's rulebook; if you ship internationally, remember that a market as different as how Ukraine handles online product sales proves the FDCA framework isn't universal, so assume nothing carries over by default.

What makes a peptide an unapproved new drug instead of a supplement?

A peptide becomes an unapproved new drug the moment its 'intended use' points at treating, curing or affecting the body — and that intent is judged by marketing, not by what the label denies. Under 21 CFR 201.128, intended use is 'the objective intent of the persons legally responsible for its labeling,' shown by labeling claims, advertising, oral or written statements, or 'the circumstances surrounding the distribution of the article.' A disclaimer sits inside that same evidentiary pool; it doesn't sit above it.

FDA's March 31, 2026 warning letter to Gram Peptides shows the test applied. The company labeled its retatrutide and tirzepatide products 'Research Use Only' and 'not intended for human consumption,' but FDA found that 'evidence obtained from your website establishes that your products are intended to be drugs for human use,' pointing specifically to mechanism-of-action copy and weight-loss claims on the product pages. The label lost to the marketing.

Even ancillary products get pulled into the classification. In the same letter, FDA held that selling bacteriostatic water alongside peptides requiring reconstitution independently proved human-use intent, reasoning that 'the sale of these products together demonstrates that you intend for your Bacteriostatic Water for Injection to be used in combination for injection.' Bundling reconstitution supplies is evidence against you, not a neutral convenience item.

Can I sell BPC-157 or ipamorelin as a dietary supplement?

No — neither fits the legal definition of a dietary supplement, and neither has a current lawful compounding pathway either. Under 21 U.S.C. 321(ff)(1), a dietary supplement must contain a vitamin, mineral, herb, amino acid or similar dietary substance from a closed statutory list; a synthetic, non-food peptide like BPC-157 doesn't qualify no matter how the label reads.

The compounding route looks tempting after 2026's headlines but doesn't actually open. BPC-157 was pulled from FDA's 503A Category 2 list in April 2026 — a procedural withdrawal by the nominators, not a safety clearance — and it appears in none of Categories 1, 2 or 3 on the May 14, 2026 update. Compounding under section 503A(b)(1)(A) requires a USP monograph, status as a component of an approved drug, or a spot on that bulks list; BPC-157 satisfies none of the three, so a licensed compounding pharmacy dispensing it sits on roughly the same legal footing as a direct-to-consumer research-peptide store — a detail few 'physician-supervised' BPC-157 clinics advertise.

July 2026's advisory committee vote didn't change that legal picture. The table below shows where the commonly sold research peptides currently stand under FDA's own published lists.

Why doesn't a 'research use only' label protect a peptide seller?

It doesn't protect you because intended use is judged by the whole marketing picture, not by a disclaimer sitting at the bottom of the page. FDA states plainly that it has 'warned companies that have illegally sold unapproved drugs containing semaglutide, tirzepatide or retatrutide that are falsely labeled for research purposes or not for human consumption' wherever 'these products have been sold directly to consumers for human use with dosing instructions.'

The FTC applies identical logic to health claims generally, not just to peptides. In one guidance example, an app claiming to treat acne carried the disclaimer 'This app is for entertainment purposes only and is not intended for the treatment of any disease or medical condition,' and FTC concluded the disclaimer was 'directly contradictory and ineffective to negate the acne treatment claim.' Dosing charts, mechanism-of-action copy and reconstitution kits all say 'human use' louder than a footer says 'research only.'

What did the FDA's 2026 peptide warning letters actually target?

They targeted the gap between what the label said and what the website actually did — mechanism-of-action claims, weight-loss promises, and bundled injection supplies. The Gram Peptides letter of March 31, 2026 is the clearest template: RUO labeling on retatrutide and tirzepatide products, contradicted by product-page copy and by bacteriostatic water sold alongside them.

Telehealth marketing drew a separate wave. On March 3, 2026, FDA announced 30 warning letters to telehealth companies over compounded GLP-1 advertising, citing 'claims implying sameness with FDA-approved products and obscuring product sourcing by advertising drug products branded with the telehealth firm's name or trademark without qualification.' FDA said it had sent more misleading-ad warning letters in the prior six months than 'over the entire preceding decade.'

That wave built on a 2025 pattern. In September 2025, FDA sent more than 50 warning letters over 'generic version' and comparative claims about compounded GLP-1s — named recipients included Hims & Hers Health, Inc. dba Hers, Lumimeds, GLP-1 Solution, GenLabMeds and The HCG Institute — alongside a separate set of RUO-labeling letters covering semaglutide, tirzepatide, retatrutide, BPC-157 and SARMs. Commissioner Marty Makary reinforced the sameness-claim line on February 6, 2026, again naming Hims & Hers.

What penalties do peptide sellers face beyond a warning letter?

Beyond the letter itself, operators face seizure, injunction, and increasingly, direct state action — not just a federal slap on the wrist. Commissioner Makary has warned publicly of possible 'seizure and injunction' for companies making unapproved sameness claims about compounded GLP-1 products.

State attorneys general are now moving faster than the warning-letter cycle. Alabama AG Steve Marshall sued Aurora IV and Wellness in November 2025 over 'pharmaceutical-grade' tirzepatide and semaglutide injections made from research-labeled material, winning a TRO that closed the business and a January 2026 settlement requiring permanent closure, roughly $24,000 in damages and penalties, and surrender of a nursing license. Connecticut AG William Tong extracted a $300,000 judgment (suspended to $18,500 on payment) against distributor Triggered Brand in May 2025 for selling raw semaglutide and tirzepatide powder, then followed up in December 2025 with cease-and-desist letters built on corporate-practice-of-medicine grounds.

Advertising platforms add a parallel enforcement layer that can shut off customer acquisition long before any regulator acts. Meta and Google both restrict prescription-drug promotion to certified pharmacies and telehealth providers, and Meta's ad review checks the landing page as well as the creative — meaning a research-peptide storefront with dosing language on its product pages can lose its ad account regardless of what the label says.

What's the difference between a compounding pharmacy and a peptide retailer?

A compounding pharmacy operates inside a licensed, prescriber-driven system with statutory limits on what it can compound; a direct-to-consumer peptide retailer generally operates inside none of that. Section 503A(b)(1)(A) permits compounding only with bulk substances that comply with a USP/NF monograph, are components of an FDA-approved drug, or appear on the 503A bulks list — a gate a plain research-peptide storefront never passes through at all.

Even inside that licensed system, GLP-1 compounding has narrowed sharply. FDA's enforcement-discretion wind-down for copying tirzepatide and semaglutide lapsed in 2025, after the agency determined the tirzepatide shortage resolved on December 19, 2024 and the semaglutide shortage resolved on February 21, 2025. A compounder can deviate from 'essentially a copy' status only with a documented, patient-specific significant-difference finding under 21 U.S.C. 353a(b)(2) or 353b(d)(2)(B), not a program-wide dosing menu, and FDA said in an April 2026 update it won't act against pharmacies filling four or fewer prescriptions of a given compound per month.

Litigation keeps the ground unstable. The semaglutide shortage-delisting question is still on appeal at the Fifth Circuit as of early 2026, and FDA has only proposed — not finalized — excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, with Commissioner Makary framing the standard as 'when FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need.' None of that litigation touches peptide retailers selling directly to consumers, because they were never operating under 503A or 503B authority to begin with.

Which peptide-adjacent products can be sold lawfully?

Food-derived peptides are the clearest lawful category. Hydrolyzed collagen and whey protein hydrolysates qualify as dietary substances under 21 U.S.C. 321(ff)(1)(D)-(F) and were marketed as food long before any drug investigation, so DSHEA's exclusion clause never reaches them — a genuinely different regulatory animal from a synthetic research peptide, and one worth checking against what supplement sellers actually keep after costs before assuming peptide-adjacent means peptide-risky.

Topical cosmetic peptides stay lawful as long as the claims stop at appearance. FDA's guidance draws the line plainly: a product 'intended to make lines and wrinkles less noticeable, simply by moisturizing the skin' is a cosmetic, but one 'intended... to remove wrinkles or increase the skin's production of collagen' is a drug. Copper peptide (GHK-Cu) shows the route-of-administration split directly — the injectable form stays flagged for immunogenicity risk and was withdrawn from nomination, while the non-injectable form was added back to Category 1 evaluation after a May 5, 2026 clarification.

Oral NAD+ precursors are lawful where the injectable form isn't. FDA reversed course on NMN in September 2025, concluding beta-nicotinamide mononucleotide is not excluded from the dietary supplement definition, though it still needs a New Dietary Ingredient notification and self-affirmed GRAS status won't substitute. Injected NAD+ sits on a different track entirely: it appears in 503A Category 1 as a bulk substance under evaluation, which makes it a compounded drug requiring a prescription, not a supplement you list on a storefront.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For educational pages, the supporting references should help readers verify search, crawlability, and public ad research context, especially Google helpful content guidance, Google SEO link best practices, and Meta Ad Library. Daily Intel then adds the direct-response interpretation layer so the page explains what the signal means for actual affiliate research decisions.

For deeper evaluation, continue through Nutra niche intelligence directory, Sinus and Allergy Offers: Seasonal Demand, Drug-Category Competition, Metabolism Offers: The Weight Loss Niche's Compliant Cousin, Colon Cleanse and Regularity Offers: Market and Drug Boundaries, Muscle and Sports Nutrition Offers: Market and Legal Boundaries, and What is a VSL?. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.